Researchers have identified plasma microRNAs miR-9 and miR-106a as significant indicators associated with peritoneal carcinomatosis in gastric cancer patients. This non-invasive biomarker panel, detailed in BMC Cancer, could facilitate early detection and prognostic assessment of this aggressive metastatic pattern. Such advancements hold promise for improving clinical management and personalized treatment strategies for gastric cancer.